Lisata Therapeutics (NASDAQ:LSTA) Posts Earnings Results, Beats Expectations By $0.39 EPS

Lisata Therapeutics (NASDAQ:LSTA) released its earnings results on Friday. The company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.39, FiscalAI reports.

Lisata Therapeutics Stock Down 5.5%

Shares of Lisata Therapeutics stock traded down $0.07 during trading on Friday, reaching $1.21. The company’s stock had a trading volume of 104,779 shares, compared to its average volume of 184,319. Lisata Therapeutics has a 52-week low of $0.96 and a 52-week high of $5.07. The company has a market cap of $13.07 million, a price-to-earnings ratio of -0.74 and a beta of 1.04. The firm’s 50-day moving average is $1.29 and its two-hundred day moving average is $2.89.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lisata Therapeutics in a research note on Wednesday. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Lisata Therapeutics has a consensus rating of “Reduce”.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for solid tumors. The company’s approach is designed to improve the delivery and effectiveness of cancer treatments by targeting the tumor microenvironment, which can limit the penetration of medicines into tumors. Lisata’s lead investigational product is certepetide, formerly known as CEND-1. Certepetide is a tumor-penetrating peptide intended to selectively home to tumor tissue and temporarily modify the tumor microenvironment, potentially helping co-administered anticancer therapies reach cancer cells more effectively.